Copy Grant Awards

CARDIOLOGY

Olujimi Ajijola, MD, PhD

NIH-NHLBI
Satellite Glial Cell Activation and Sympathetic Imbalance in Cardiomyopathy and Arrhythmias
$1,452,057

Jesus Araujo, MD, PhD

NIH/NIEHS
Dissecting the Role of Arachidonic Acid Metabolic Pathways Involved in Resolution Versus Progression of PM-Induced Cardiometabolic Toxicity
$2,125,089

Srinivasa Reddy, PhD

NIH
Novel Approaches for Improving Inflammation Resolution Following Chronic Exposure to Air Pollutant
$1,195,956

Yucheng Yao, MD, PhD

NIH-NHLBI
Switch of Osteogenesis in Vascular Calcification
$1,000,000

Yucheng Yao, MD, PhD

NIH/NINDS
BMP and Notch Crosstalk in Cerebral Arteriovenous Malformations
$1,250,000

CARE CENTER

Kara Chew, MD

NIH
UCLA-CDU CFAR
$1,051,678

Raphael Landovitz, MD

NIH
UCLA-CDU CFAR
$67,236

Raphael Landovitz, MD

NIH
AIDS Malignancy Consortium
$129,000

Raphael Landovitz, MD

NIH-NIAID/ FHI360
Bexsero DMID 19-0004 MAGI
$150,000

Judith Currier, MD

NIH-NIAID
Centers for AIDS Research
$53,682

CLINICAL NUTRITION

Zhaoping Li, MD, PhD

NIH
California Partnership for Personalized Nutrition
$2,838,813
$3,639,504

Zhaoping Li, MD, PhD

NIH
UCLA and All of Us
$1,000,000

DERMATOLOGY

Robert Modlin, MD

NIH
Dynamics of the Cellular and Molecular Architecture of Human Pulmonary TB Granulomas
$3,268,826

Robert Modlin, MD

NIH/NIAID
Acne: A Disease of Lipid Metabolism, Microbiome, and the Immune Response
$7,846,616

DIGESTIVE DISEASES/ GASTROENTEROLOGY

Hon Koon, PhD

NIH – NIDDK
Oral Elafin Formulation for Intestinal Fibrosis
$1,453,610

Enrique Rozengurt, DVM, PhD

NIH
Interaction Between Chronic Stress and Obesity in Pancreatic Cancer Progression
$218,790

ENDOCRINOLOGY

Estelle Marla Everett

NIH-NIDDK
Hybrid Closed Loop Insulin Pump use in Poorly Controlled Type 1 Diabetes
$946,214

EPI

Karol Watson, MD, PhD

Northwestern University/NIH
Contributions of Stress Reactivity to Risk of Alzheimer’s Disease and Related Dementias in a Community-Based Cohort
$311,610

Karol Watson, MD, PhD

Brigham and Women's Hospital/NIH
Longitudinal Relationships Among Sleep, Cognition and Alzheimer’s Disease Biomarkers: Discerning Causal Associations, Mediators, and Susceptibility
$631,817

Karol Watson, MD, PhD

Wake Forest University/NIH
Glucose Homeostasis and the Risk of Alzheimer's Disease and Alzheimer's Disease Related Dementias in the Multi-Ethnic Study of Atherosclerosis
$213,950

Karol Watson, MD, PhD

Columbia University/NIH
Leveraging the 24-Hour Movement Paradigm to Preserve Cognitive Function and Prevent Alzheimer’s Disease: The Multi-Ethnic Study of Atherosclerosis
$360,618

GIMHSR

Alejandra Casillas, MD

NIH/NIMHD
TELE Para DM: Telemedicine Equity for Limited English Proficient Patients with Diabetes Mellitus in the Safety Net $812,000

Kenrik Duru, MD

NIH/NIDDK A Multi-Level Evaluation of California's New Medicaid Coverage for the Diabetes Prevention Program
$142,798

Lauren Wisk, PhD

NIH/NIDDK
Motivating Parental Support of Youth Skill-Building During Health Care Transition
$150,000

GERIATRICS

Steve Cole, PhD & Teresa Seeman, PhD

NIH-National Institute on Aging
Enhancing Innate Anti-Viral Resistance Through a Community-Based Intervention
$638,992

Arun S. Karlamangla, MD, PhD

NIH-National Institute on Aging
The Study of Women’s Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age
$106,230

HEMATOLOGY-ONCOLOGY

Jerome Zack, PhD

NIH-NIAID
UCLA-CDU CFAR
$8,907,130

Anjie Zhen, PhD

NIH
Induction of Autophagy to Enhance Car-T Cells in HIV Cure Approaches
$3,909,999

INFECTIOUS DISEASES

Igor Barjaktarevic, MD, PhD

University of Alabama (UAB)
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency (ATALANTa) A Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of alvelestat (MPH966) in alpha-1 antitrypsin deficiency
$41,304

Judith S. Currier, MD

NIH
ACTIV-2D (A5407)
$139,891,696

Judith S. Currier, MD

NIH/NIAID
CoVPN 3001 and CoVPN 3002
$4,731,094

Judith S. Currier, MD

NIH/NIAID
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
$9,723,638

Jerome Zack, MD, Judith Currier, MD, LaShonda Spencer, MD

NIH/NIAID
UCLA-CDU CFAR
$11,250,015

PULMONARY DISEASES

David Shackelford, PhD

NIH
In Vivo Imaging of Mitochondria Structure and Function in Therapy Resistant Lung Tumors
$2,292,725

VETERANS AFFAIRS

Ilya Gukovsky, MD

NIH /NIAID
Impaired Autophagy, Mitochondrial Dysfunction, and Inflammation in Pancreatitis
$1,572,097

Tzung Hsiai, MD, PhD

NIH-National Institute of Environmental Health Sciences
Novel Approaches for Improving Inflammation Resolution Following Chronic Exposure to Air Pollutants
$459,807

Tzung Hsiai, MD, PhD

NIH - National Health, Lung and Blood Institute
Kilohertz 3D Optical Mapping of Atrial Fibrillation in Beating Zebrafish Hearts
$627,852

Monica Kelly, MD

NIH/NHLBI
Insomnia Treatment and Cardiometabolic Health in Older Adults with Posttraumatic Stress Disorder
$986,747

Kim-Lien Nguyen, MD

NIH/NHLBI
Expanding on a new paradigm for MRI in pediatric CHD $1,768,275.64

Kim-Lien Nguyen, MD

NIH/NHLBI
Expanding on a New Paradigm for MRI in Pediatric Congenital Heart Disease
$46,093

CARDIOLOGY

Reza Ardehali, MD, PhD

University of Wisconsin/Department of Defense
Defining Cardiac Innervation and Reinnervation During Cardiac Injury
$37,499

CLINICAL NUTRITION

Zhaoping Li, MD, PhD

Veterans Affairs
Pomegranate Extract and Its Microbial Metabolite Urolithin A Suppress IBD through Modulation of the Gut Microbiome and T Cell Inflammatory Immune Responses
$700,000

Zhaoping Li, MD, PhD

National Comprehensive Cancer Network
Contribution of Race to Nutritional Approach to Lower Cardiovascular Risk Factors in Men Undergoing Androgen Deprivation Therapy
$198,333
$199,660

GIMHSR

Tannaz Moin, MD & Kenrik Duru, MD

CDC
Evaluating Real-World Diabetes Prevention Programs in a Multi-campus University System and a Three State Regional Health Network
$2,582,764

INFECTIOUS DISEASES

Jesse Clark, MD

Fred Hutchinson Cancer Research Center
A phase 1, Randomized, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-Uninfected Adult Participants
$64,464

PULMONARY DISEASES

Igor Barjaktarevic, MD, PhD

NHLBI
Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
$294,725

VETERANS AFFAIRS

Blessen Eapen, MD

University of Texas- Health Science Center at San Antonio
Multisite Advancement of Research for Chronic Post-Traumatic Headache
$643,052

Daniel Shin, MD

Department of Defense
CAR- T Cell Therapy for Rare Melanoma Targeting TYRP1
$175,000

CARDIOLOGY

Arjun Deb, MD

California Institute for Regenerative Medicine Targeting Stromal Progenitors to Prevent the Development of Heart Failure
$4,000,000

CARE Center

Raphael Landovitz, MD

LA County-Department of Public Health
Core HIV Medical Services for Persons Living with HIV (MCC)
$2,723,795

Raphael Landovitz, MD

LA County-Department of Public Health
Core HIV Medical Services for Persons Living with HIV (AOM)
$1,769,707

GIMHSR

David E. Hayes-Bautista, PhD

CA-Dept. of Healtt Care Access and Information
MEDPEP 2022-2023
$19,999

Alice Kuo, MD

Public Health Advocates
All Children Thrive, California (ACT-CA) 2022
$6,826,493

Carol Mangione, MD

CA-Department of Health Care Access and Information
UCLA Allied Healthcare Careers Program Conference
$21,151

Keith Norris, MD, PHD and Arleen Brown, MD, PhD

CA-California Government Operations Agency
California Get Out the Vaccine Campaign to Stop COVID-19 (GOTV)
$11,895,000

David Zingmond, MD

One Legacy
California OSHPD PDD and EDD Data Analysis to Determine Organ Donor Potential in California
$20,090

GERIATRICS

David B. Reuben, MD

UCSF / California Department of Health Care Services
Dementia Aware
$1,901,409

PULMONARY DISEASES

Bin Liu, PhD

TRDRP
Engineered Chimeric Antigen Receptor-Natural Killer Cellular Therapy for Non-small Cell Lung Cancer
$900,000

CARDIOLOGY

Arjun Deb, MD

Stanton H. Wong Survivor's Trust
$100,000

Gregg C. Fonarow, MD

National Cardiovascular Research Foundation
$110,000

Jeffrey Hsu, MD, PhD

American Heart Association
The Role of Viral Fragments in Long-Term Cardiovascular Sequelae of COVID-19
$909,093

Kamran Shamsa, MD

Rudy Family Foundation
$50,000

CLINICAL NUTRITION

Zhaoping Li, MD, PhD

American Heart Association
Improving Participation in Multi-Ethnic Populations to Personalized Dietary to Mitigate Cardiometabolic Diseases
$1,188,000

Zhaoping Li, MD, PhD

Hirschberg Foundation
$60,000

DERMATOLOGY

Philip Scumpia, MD, PhD

LEO Foundation (Denmark)
Immunomodulatory Porous Biomaterials for Skin Regeneration
$564,150

Philip Scumpia, MD, PhD

American Cancer Society
$779,012

Amy Vandiver, MD

Dermatology Foundation Career Development Award
$55,000

DIGESTIVE DISEASES/GASTROENTEROLOGY

Eric Esrailian, MD

Schwab Charitable Fund, Jim & Carmen Ward Fund
$200,000

ENDOCRINOLOGY

Matthew Freeby, MD

The Gonda Foundation
$269,882

GIMHSR

Emily Hotez, PhD

American College of Preventive Medicine
A Quality Improvement Initiative to Prevent, Mitigate and Treat COVID-19 in Minoritized Populations in the UCLA Division of Internal Medicine-Pediatrics
$242,091

Emily Hotez, PhD

Association of University Centers on Disabilities
A proposal for UC-LEND as the Pac-West Regional Hub for COVID-19 Vaccine Outreach
$13,219

Katie Hu, MD

Star Family Foundation
$125,000

Ka Kit Hui, MD

PAMC Health Foundation
$25,000

John Mafi, MD

Laura and John Arnold Foundation
The Effects of Telemedicine on the Accessibility, Costs, and Affordability of Care During the COVID-19 Pandemic
$451,154

Janet Pregler, MD

The Nesburn Family Foundation
$2,000

Janet Pregler, MD

National Philanthropic Trust Peacock Family
$10,000

Janet Pregler, MD

Cathay Bank Foundation
$15,000

Janet Pregler, MD

Dermavant Sciences
$100,000

Neil Wenger, MD

Western Cardiac Foundation
$30,000

GERIATRICS

Teresa E. Seeman, PhD

The Nicholas Endowment Generation Xchange
Phase 2/Year2: Supporting Intergenerational Academic & Social/Emotional Learning
$55,000

David B. Reuben, MD

Arthur N. Rupe Foundation
Training Dementia Care Assistants to Support Successful Dementia Care Programs
$125,312

HEMATOLOGY-ONCOLOGY

Gottfried E. Konecny, MD

The Honorable Tina Brozman Foundation Inc.
Non-invasive liquid biopsy approach for early detection of ovarian cancer using cell free DNA fragmentation patterns
$272,728

INFECTIOUS DISEASES

Division of Infectious Diseases

Jewish Community Foundation, Doren Family Foundation Fund
$50,000

Otto Yang, MD

Campbell Foundation
Escape from HIV-Specific Chimeric Antigen Receptors
$90,000

NEPHROLOGY

Ira Kurtz, MD

The Stanley and Joyce Family Foundation
$15,000

Ira Kurtz, MD

Donald Sterling Charitable Trust
$50,000

PULMONARY DISEASES

Igor Barjaktarevic, MD, PhD

Johnny Carson Foundation
$112,000

RHEUMATOLOGY

John Fitzgerald, MD

Arthritis Foundation
Development of an Informed Decision-Making Intervention to Address Under-Utilization of Total Knee Replacement for African-American Patient
$50,000

Christina Charles-Schoeman, MD

Simon-Strauss Foundation
$20,000

VETERANS AFFAIRS

Tzung Hsiai, MD, PhD

American Heart Association
Integrated Community Engaged, mHealth, and Data Science to Enhance Clinical Trial Diversity and Cardiometabolic Health
$4,200,000

DIGESTIVE DISEASES/GASTROENTEROLOGY

Raman Muthusamy, MD

Boston Scientific Corp.
Exalt DScope 02: Global Prospective Case Series Using a Single-Use Duodenoscope
$187,943

HEMATOLOGY-ONCOLOGY

Wanxing Chai-Ho, MD

AbbVie Inc.
A PHASE 1 OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY, AND PHARMACOKINETICS OF NAVITOCLAX ALONE AND IN COMBINATION WITH RUXOLITINIB IN MYELOPROLIFERATIVE NEOPLASM SUBJECTS (PROTOCOL# M19-753)
$207,994

Bartosz Chmielowski, MD, PhD

Adagene
A FIRST-IN-HUMAN (FIH), OPEN-LABEL, PHASE I DOSE ESCALATION AND EXPANSION STUDY OF ADG126, ADG126 IN COMBINATION WITH TORIPALIMAB, AND ADG126 IN COMBINATION WITH ADG106 IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS PROTOCOL NO. ADG126-1001
$1,028,245

Bartosz Chmielowski, MD, PhD

Kinnate Biopharma, Inc.
A PHASE 1/1B OPEN-LABEL, MULTICENTER, TWO PART STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF KIN-2787 IN SUBJECTS WITH BRAF MUTATION POSITIVE SOLID TUMORS
$529,928

Bartosz Chmielowski, MD, PhD

Surefire DBA TriSalus Life Sciences
A PHASE 1/1B, OPEN-LABEL STUDY OF THE PRESSURE-ENABLED HEPATIC ARTERY INFUSION OF SD-101, A TLR9 AGONIST, ALONE OR IN COMBINATION WITH INTRAVENOUS CHECKPOINT BLOCKADE IN ADULTS WITH METASTATIC UVEAL MELANOMA (PROTOCOL# TS-PERIO-01)
$282,467

Amy Cummings, MD

Novartis Pharmaceuticals #CINC280AU212
PHASE II TRIAL OF NEOADJUVANTAND ADJUVANTCAPMATINIB IN PARTICIPANTSWITH STAGES IB-IIIA, N2 AND SELECTED IIIB(T3N2 OR T4N2) NSCLC WITHMET EXON 14 SKIPPING MUTATION OR HIGH MET AMPLIFICATION- GEOMETRY-N (PROTOCOL#CINC280AUS12)
$172,612

Sven de Vos, MD, PhD

MEMORIAL SLOAN-KETTERING CANCER CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH TREATMENT NA VE MARGINAL ZONE LYMPHOMA
$82,198

Jonathan Goldman, MD

AstraZeneca LP
A PHASE III, RANDOMISED, CONTROLLED, MULTI-CENTRE, 3-ARM STUDY OF NEOADJUVANT OSIMERTINIB AS MONOTHERAPY OR IN COMBINATION WITH CHEMOTHERAPY VERSUS STANDARD OF CARE CHEMOTHERAPY ALONE FOR THE TREATMENT OF PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE, RESECTABLENON-SMALL CELL LUNG CANCER (NEOADAURA) (PROTOCOL# D516AC00001)
$136,808

Jonathan Goldman, MD

ASTRAZENECA PLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, INTERNATIONAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADJUVANT OSIMERTINIB VERSUS PLACEBO IN PARTICIPANTS WITH EGFR MUTATION POSITIVE STAGE IA2-IA3 NON-SMALL CELL LUNG CANCER, FOLLOWING COMPLETE TUMOR RESECTION (ADAURA2) (PROTOCOL# D516FC00001)
$160,661

Jonathan Goldman, MD

ELI LILLY AND COMPANY
LIBRETTO-432 : A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIARETFUSION- POSITIVE NSCLC
$293,498

Joel Randolph Hecht, MD

Tizona Therapeutics, Inc.
A PHASE 1A/1B DOSE ESCALATION/EXPANSION STUDY OF TTX-080, AND HLA-G ANTAGONIST, AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB OR CETUXIMAB IN PATIENTS WITH ADVANCED SOLID REFRACTORY/RESISTANT MALIGNANCIES (PROTOCOL #TTX-080-001)
$1,026,344

Gottfried E. Konecny, MD

Sutro Biopharma, Inc.
A PHASE 1 OPEN-LABEL, SAFETY, PHARMACOKINETIC AND PRELIMINARY EFFICACY STUDY OF STRO-002, AN ANTI-FOLATE RECEPTOR ALPHA (FOLRA) ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER (INCLUDING FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCERS) AND ENDOMETRIAL CANCERS (PROTOCOL# STRO-002-GM1)
$78,709

Sarah Larson, MD

Allogene Therapeutics #ALLO-605-201
A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-647 AND ALLO-605, AN ANTI-BCMA ALLOGENEIC CAR T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (PROTOCOL# ALLO-605-201)
$214,518

Nicholas P. McAndrew, MD

SeaGen, Inc.
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2+ BREAST CANCER (HER2CLIMB-05)
$120,375

Kelly E McCann, MD, PhD

ELI LILLY AND COMPANY
ROLLOVER PROTOCOL FOR CONTINUED SAFETY ASSESSMENT OF STUDY DRUG LY302414
$93,129

Gary J. Schiller, MD

Biomea Fusion, Inc.
A PHASE 1 FIRST-IN-HUMAN DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF BMF-219, AN ORAL IRREVERSIBLE MENIN INHIBITOR, IN ADULT PATIENTS WITH ACUTE LEUKEMIA INCLUDING THOSE WITH AN MLL/KMT2A GENE REARRANGEMENT OR NPM1 MUTATION (PROTOCOL# BF-MNN-101)
$313,750

Gary J. Schiller, MD

IMMUNOGEN, INC.
A PHASE 1/2, MULTI-CENTER, OPEN-LABEL STUDY OF IMGN632 MONOTHERAPY ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH CD123-POSITIVE ACUTE MYELOID LEUKEMIA AND OTHER CD123-POSITIVE HEMATOLOGIC MALIGNANCIES PROTOCOL IMGN632-0801
$1,004,116

Gary J. Schiller, MD

Kronos Bio, Inc. #KB-LANRA-1001
A PHASE 1B/2 STUDY OF THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB (LANRA) IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN PATIENTS WITH FLT3-MUTATED RELAPSED OR REFRACTORY AML PROTOCOL NUMBER KB-LANRA-1001
$100,094

John Shen, MD

Arvinas, Inc #ARV-110-MCRPC-103
A PHASE 1B OPEN-LABEL CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ARC-110 IN COMBINATION WITH ABRIATERONE IN PATIENTS WITH METASTATIC PROSTATE CANCER PROTOCOL# ARV-110-MCRPC-103
$169,039

Zev A. Wainberg, MD

ALX Oncology #AT148006
A PHASE 2/3 STUDY OF A1x148 IN PATIENTS WITH ADVANCED HER2-OVEREXPRESSING GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (Aspen-06) (PROTOCOL# AT148006)
$381,149

Zev A. Wainberg, MD

Amgen #20210096 (FORTITUDE 101)
A RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF BEMARITUZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER WITH FGFR2B OVEREXPRESSION (FORTITUDE-101) (PROTOCOL# 20210096)
$463,955

Zev A. Wainberg, MD

Amgen #20210098 (FORTITUDE 102)
A PHASE 1B/3 STUDY OF BEMARITUZUMAB PLUS CHEMOTHERAPY AND NIVOLUMAB VERSUS CHEMOTHERAPY AND NIVOLUMAB ALONE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED GASTRIC AND GASTROESOPHAGEAL CANCER WITH FGFR2B OVEREXPRESSION PROTOCOL NO. 20210098
$486,772

Zev A. Wainberg, MD

ELICIO ELI
FIRST IN HUMAN PHASE 1/2 TRIAL OF ELI- 002 IMMUNOTHERAPY AS TREATMENT FOR SUBJECTS WITH KIRSTEN RAT SARCOMA (KRAS) MUTATED PANCREATIC DUCTAL ADENOCARCINOMA AND OTHER SOLID TUMORS (PROTOCOL# ELI- 002- 001)
$433,444

Zev A. Wainberg, MD

GENENTECH, INC.
A PHASE I/IB GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER (INTRISIC)
$117,438

Zev A. Wainberg, MD

Syros Pharmaceuticals Inc.
PHASE 1 STUDY OF SY-5609, AN ORAL, SELECTIVE CDK7 INHIBITOR, IN ADULT PATIENTS WITH SELECT ADVANCED SOLID TUMORS (PROTOCOL# SY-5609-101)
$384,983

Zev A. Wainberg, MD

TORL Biotherapy
A PHASE 1, FIRST IN HUMAN, DOSE- ESCALATION STUDY OF TORL- 2- 307- MAB IN PARTICIPANTS WITH ADVANCED CANCER (PROTOCOL# TORL2307MAB- 001)
$167,985

Zev A. Wainberg, MD

Translational Research in Oncology (Canada)
A PHASE 1, FIRST IN HUMAN, DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (PROTOCOL# TORL2307ADC-001)
$495,661

Zev A. Wainberg, MD

TRETHERA Corp
A PHASE 1, OPEN- LABEL, FIRST- IN- HUMAN, DOSE- ESCALATION STUDY WITH EXPANSION TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORALLY ADMINISTERED TRE- 515 IN SUBJECTS WITH SOLID TUMORS (PROTOCOL# TRE515- T- 02)
$333,966

Deborah Wong, MD, PhD

Bicara Therapeutics Inc. #BCA101X1101
FIRST-IN-HUMAN, PHASE 1/1B, OPEN-LABEL, MULTICENTER STUDY OF BIFUNCTIONAL EGFR/TGFΒ FUSION PROTEIN BCA101 MONOTHERAPY AND IN COMBINATION THERAPY IN PATIENTS WITH EGFR-DRIVEN ADVANCED SOLID TUMORS (PROTOCOL# BCA101X1101)
$513,938

NEPHROLOGY

Niloofar Nobakht, MD

Chinook Therapeutics Inc.
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function
$375,484

Anjay Rastogi, MD

Bayer Healthcare LLC
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients with Non-Diabetic Chronic Kidney Disease (Protocol# 21177)
$200,358

PULMONARY DISEASES

Igor Barjaktarevic, MD, PhD

Grifols Therapeutics Inc.
A MC, SD and Repeat Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety & Tolerability as well as Pharmacokinetics of Two Different Doses of Alpha-Proteinase of Two Different Doses of Alpha-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subject with Alpha-Antitrypsin Deficiency
$321,039

CARDIOLOGY

Olujimi Ajijola, MD, PhD

Heart Rhythm Society, Inc.
Masuyama, Kiyoshi: Mechanistic Control of Electrical Propagation by the Sympathetic Nervous System in Infarcted Hearts: A “Bedside to Bench to Bedside"
$50,000

Noel Boyle, MD, PhD

Abbott Laboratories
Abbott/St.Jude CCEP Fellowship FY 22-23
$60,000

Noel Boyle, MD, PhD

Biotronik Inc.
Biotronik CCEP fellowship grant AY 22-23
$25,000

Noel Boyle, MD, PhD

Boston Scientific Foundation
Boston Scientific CCEP Fellowship FY 22-23
$15,000

Noel Boyle, MD, PhD

Medtronic
Medtronic HRS Scholarship AY 22-23
$4,000

Noel Boyle, MD, PhD

Medtronic
Medtronic CCEP Fellowship FY 2022-2023
$20,000

Noel Boyle, MD, PhD

Sorin CRM SAS (France)
Educational Grant for Stipend Support of Clinical/Research Fellow at the Cardiac Arrhythmia Center, May 2022 - May 2024
$45,000

Ravi Dave, MD

Medtronic
Interventional Cardiology Fellowship AY22-23
$8,000

Sachin Sharma, PhD

American Heart Association
Devising Cell-Specific Novel Anti-Adrenergic Therapies for Heart Failure and Ventricular Arrhythmias
$160,284

GIMHSR

Alice Kuo, MD

HRSA/DHHS
Graduate Pychology Education Programs
$1,255,263

CARDIOLOGY

Rene Packard, MD, PHD

2022 CTSI-DGSOM THEME AWARD
PRECISION MEDICINE BY IMMUNO-PET IMAGING OF SERINC-3 TO DIAGNOSE ANTHRACYCLINE-INDUCED CARDIOTOXICITY
$125,000

GIMHSR

Priyanka Fernandes, MPH

REDUCING DISPARITIES IN MATERNAL AND CHILD HEALTH OUTCOMES: USING QUALITATIVE AND QUANTITATIVE
$125,000